• 1
    Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 133040.
  • 2
    Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 161620.
  • 3
    Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 240817.
  • 4
    de Lavallade H, Apperley JF, Khorashad JS et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 335863.
  • 5
    Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 78999.
  • 6
    Hasford J, Pfirrman M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee of the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 8508.
  • 7
    Hasford J, Baccarian M, Hoffman V et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 68692.
  • 8
    Kantarjian H, Talpaz M, O'Brien S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha. Clin Cancer Res 2002; 8: 217787.
  • 9
    Langabeer SE, Gale RE, Harvey RC et al. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia 2002; 16: 3939.
  • 10
    Yagasaki F, Niwa T, Abe A et al. Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki 2009; 50: 4817. (In Japanese).
  • 11
    Ohnishi K, Nakaseko C, Takeuchi J et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 2012; 103: 10718.
  • 12
    Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 604151.
  • 13
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 4528.
  • 14
    Martin D, Ibrahim AR, Goldman JM et al. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011; 29: 39445.
  • 15
    Jabbour E, Cortes J, Nazha A et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 2012; 119: 45246.
  • 16
    Breccia M, Finsinger P, Loglisci G et al. The EUTOS score identifies chronic myeloid leukemia patients with poor prognosis treated with imatinib first or second line. Leuk Res 2012; 36: e20910.
  • 17
    Uz B, Buyukasik Y, Atay H et al. EUTOS CML prognostic scoring system predicts ENL-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology 2013; 18: 24752.
  • 18
    Pagnano KB, Lorand-Metze I, Miranda EC et al. EUTOS score is predictive of event-free survival, but not for progressive-free and overall survival in patients with early chronic phase chronic myeloid leukemia treated with imatinib: a single institute experience. Blood 2012; 120 (ASH abstract no. 1681).
  • 19
    Yahng SA, Jang EJ, Choi SY et al. Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each model: a single center date analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood 2012; 120 (ASH abstract no. 2794).
  • 20
    Than H, Kuan LY, Seow CH et al. The EUTOS score is highly predictive for clinical outcome and survival in Asian patients with early chronic phase chronic myeloid leukemia treated with imatinib. Blood 2012; 120 (ASH abstract no. 3758).
  • 21
    Tiribelli M, Bonifacio M, Calistri E et al. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukemia. Leuk Res 2013; 37: 145760.
  • 22
    Hoffmann VS, Baccarani M, Lindoerfer D et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 201622.
  • 23
    Marin D, Bazeos A, Mahon FX et al. Adherence is the clinical factor for achieving molecular response in patients with chronic myeloid leukemia who achieve complete cytogenic response on imatinib. J Clin Oncol 2010; 28: 23818.
  • 24
    Jabbour E, Saglio G, Radich J et al. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk 2012; 12: 2239.
  • 25
    Singh O, Chan JY, Lin K, Heng CC, Chowbay B. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS ONE 2012; 7: e51771.